SEC Insider Transactions from Gallagher Neil.

Last updated: 2026-03-14 11:14 UTC | Total transactions: 11

Gallagher Neil has filed 11 insider transactions across 3 companies since April 2023.

Most recent transaction: a grant/award of 50000 shares of Foghorn Therapeutics Inc. ($FHTX) on May 01, 2025.

Activity breakdown: 0 open-market purchases and 1 sale.

Set Up your own filters →
Transaction Date Company Ticker Insider Name Title Transaction Type Security Shares Price Shares Owned Following Total Shares Outstanding % of Owned % of Outstanding
May 1, 2025 Foghorn Therapeutics Inc. $FHTX Gallagher Neil Not found A Stock Options (Right to buy) 50000 $4.16 50,000.0000 54,899,432 9999.99% 0.09%
Feb. 10, 2025 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D S Common Stock 4618 $15.50 85,095.0000 0 5.15% 0.00%
Feb. 5, 2025 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D A Stock Options (Right to buy) 110500 $14.65 110,500.0000 0 9999.99% 0.00%
Feb. 5, 2025 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D A Common Stock 23400 $0.00 89,713.0000 0 35.29% 0.00%
Feb. 5, 2025 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D A Common Stock 18500 $0.00 66,313.0000 0 38.69% 0.00%
Dec. 10, 2024 Zymeworks Inc. $ZYME Gallagher Neil Not found A Stock Option (Right to Buy) 31000 $0.00 31,000.0000 76,266,177 9999.99% 0.04%
April 2, 2024 Zymeworks Inc. $ZYME Gallagher Neil Not found A Stock Option (Right to Buy) 74000 $0.00 74,000.0000 68,863,010 9999.99% 0.11%
Feb. 7, 2024 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D A Common Stock 34688 $0.00 34,688.0000 0 9999.99% 0.00%
Feb. 7, 2024 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D A Common Stock 13125 $0.00 47,813.0000 0 37.84% 0.00%
Feb. 7, 2024 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D A Stock Options (Right to buy) 69375 $22.28 69,375.0000 0 9999.99% 0.00%
April 10, 2023 Syndax Pharmaceuticals Inc $SNDX Gallagher Neil President, Head of R&D A Stock Options (Right to buy) 250000 $19.35 250,000.0000 0 9999.99% 0.00%